MA41120A - Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci - Google Patents

Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Info

Publication number: MA41120A
Authority: MA; Morocco
Prior art keywords: hepe; treating; methods; compositions including; preventing fibrosis
Prior art date: 2014-12-02

Application number

MA041120A

Other languages

English (en)

Inventor

John Climax

Kevin Duffy

Jonathan Rowe

Original Assignee

Afimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-02

Filing date

2015-12-01

Publication date

2017-10-10

2015-12-01 Application filed by Afimmune Ltd filed Critical Afimmune Ltd

2017-10-10 Publication of MA41120A publication Critical patent/MA41120A/fr

Links

WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 title 1
206010016654 Fibrosis Diseases 0.000 title 1
230000004761 fibrosis Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA041120A 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci MA41120A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462086535P	2014-12-02	2014-12-02

Publications (1)

Publication Number	Publication Date
MA41120A true MA41120A (fr)	2017-10-10

Family

ID=56092410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA041120A MA41120A (fr)	2014-12-02	2015-12-01	Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Country Status (17)

Country	Link
US (1)	US10363235B2 (fr)
EP (2)	EP3226873B1 (fr)
JP (2)	JP6986445B2 (fr)
KR (1)	KR20170102879A (fr)
CN (2)	CN107206008A (fr)
AU (2)	AU2015358512B2 (fr)
BR (1)	BR112017011685A2 (fr)
CA (1)	CA2968980A1 (fr)
ES (1)	ES2900593T3 (fr)
IL (2)	IL252431B (fr)
MA (1)	MA41120A (fr)
MX (2)	MX382116B (fr)
PH (1)	PH12017501022B1 (fr)
RU (2)	RU2721555C2 (fr)
SG (2)	SG11201704495VA (fr)
WO (1)	WO2016090030A1 (fr)
ZA (2)	ZA201704463B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja)	2013-11-15	2016-12-08	ディグニティサイエンシスリミテッド	多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (fr) *	2014-01-10	2017-09-20	Dignity Sciences Limited	Compositions pharmaceutiques comprenant le 15-hepe et méthodes de traitement de l'asthme et de pathologies pulmonaires à l'aide desdites compositions
US20180008567A1 (en) *	2015-01-16	2018-01-11	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
MA47141A (fr)	2015-05-13	2019-11-06	Ds Biopharma Ltd	Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
CA3129008A1 (en) *	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180671B1 (en) *	1998-03-10	2001-01-30	Beth Israel Deaconess Medical Center, Inc.	Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja)	1998-12-25	2000-07-11	Nof Corp	皮膚外用剤組成物
WO2001049282A2 (fr) *	2000-01-06	2001-07-12	Martek Biosciences Corporation	Preparations therapeutiques d'acides gras fortement insatures
EP1762557B1 (fr)	2000-02-16	2011-04-06	The Brigham And Women's Hospital, Inc.	Mediateurs lipidiques actives par l'aspirine
JP2005179211A (ja)	2003-12-17	2005-07-07	Idemitsu Kosan Co Ltd	皮膚外用剤組成物
EP1711173A2 (fr)	2003-12-31	2006-10-18	Igennus Limited	Formulation contenant de l'acide eicosapentaenoique ou un ester de celui-ci et d'un triterpene ou un ester de celui-ci
WO2005102309A2 (fr)	2004-04-26	2005-11-03	Ltb4 Sweden Ab	Liberation in vivo de mediateurs endogenes antimicrobiens par administration de leukotriene b4 (ltb4)
EP3285072B1 (fr) *	2006-08-08	2020-04-15	Metabolon, Inc.	Marqueurs de maladie du foie gras non alcoolique (nafld) et de la stéatohépatite non alcoolique (nash) et leurs procédés d'utilisation
US8042070B2 (en) *	2007-10-23	2011-10-18	International Business Machines Corporation	Methods and system for analysis and management of parametric yield
GB0802116D0 (en) *	2008-02-05	2008-03-12	Natural Enviromental Res Counc	Treatment
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
US20110105510A1 (en)	2008-06-17	2011-05-05	Hiroshi Ishikawa	Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010120880A1 (fr) *	2009-04-14	2010-10-21	Vertex Pharmaceuticals Incorporated	Traitement de maladies hépatiques avec un inhibiteur de caspase
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
US10154977B2 (en) *	2011-03-25	2018-12-18	The Brigham And Women's Hospital, Inc.	Anti-inflammatory particles
US20120264824A1 (en) *	2011-04-15	2012-10-18	Mochida Pharmaceutical Co., Ltd.	Compositions and methods for treating non-alcoholic steatohepatitis
MX360979B (es) *	2011-09-16	2018-11-22	Galectin Therapeutics Inc	Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
RU2014119948A (ru)	2011-10-19	2015-11-27	Дигнити Сайенсиз Лимитед	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja)	2011-11-29	2015-01-08	ディグニティサイエンシスリミテッド	２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CN104302305A (zh) *	2011-12-16	2015-01-21	塔瑞克斯制药有限公司	用于治疗纤维化的血管紧张素
US20120264705A1 (en)	2012-01-26	2012-10-18	Dignity Sciences Limited	Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en)	2012-02-23	2013-10-10	Dignity Sciences Limited	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da)	2012-05-10	2023-07-24	Solutex Na Llc	Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) *	2013-03-15	2021-10-11	英商邊緣生物科技有限公司	用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CA3129008A1 (en)	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same

2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/fr not_active Ceased
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja not_active Expired - Fee Related
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/fr active Active
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
- 2015-12-02 CA CA2968980A patent/CA2968980A1/fr not_active Abandoned
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Withdrawn
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
- 2015-12-02 MX MX2017007000A patent/MX382116B/es unknown
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/fr not_active Withdrawn
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022B1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
2018
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending

Also Published As

Publication number	Publication date
IL287983A (en)	2022-01-01
MX382116B (es)	2025-03-13
CN107206008A (zh)	2017-09-26
ZA201704463B (en)	2018-11-28
ES2900593T3 (es)	2022-03-17
JP6986445B2 (ja)	2021-12-22
US20160184252A1 (en)	2016-06-30
MX2021005080A (es)	2021-06-15
IL252431B (en)	2021-12-01
US10363235B2 (en)	2019-07-30
MX2017007000A (es)	2017-12-07
RU2017122758A (ru)	2019-01-09
SG10202010594WA (en)	2020-12-30
IL252431A0 (en)	2017-07-31
EP3226873A1 (fr)	2017-10-11
CA2968980A1 (fr)	2016-06-09
PH12017501022B1 (en)	2022-02-16
RU2020115523A (ru)	2021-01-27
RU2017122758A3 (fr)	2019-06-13
EP3226873B1 (fr)	2021-10-27
RU2721555C2 (ru)	2020-05-20
SG11201704495VA (en)	2017-06-29
PH12017501022A1 (en)	2017-11-27
JP2022031813A (ja)	2022-02-22
HK1245101A1 (zh)	2018-08-24
AU2015358512B2 (en)	2021-02-18
AU2021203189A1 (en)	2021-06-10
EP3226873A4 (fr)	2018-08-08
AU2015358512A1 (en)	2017-07-20
KR20170102879A (ko)	2017-09-12
ZA201804380B (en)	2021-03-31
WO2016090030A1 (fr)	2016-06-09
BR112017011685A2 (pt)	2018-01-02
JP2017536380A (ja)	2017-12-07
EP3988101A1 (fr)	2022-04-27
CN112245419A (zh)	2021-01-22

Publication	Publication Date	Title
EP3658612A4 (fr)	2021-06-02	Formation de particules comprenant des agents
EP3481434A4 (fr)	2020-06-24	Compositions à base de crispr/cas9 et méthodes de traitement de dégénérescences de la rétine
MA46481A (fr)	2019-08-14	Compositions d'oligonucléotides et méthodes associées
MA45192A (fr)	2019-04-10	Traitement d'association
EP3344274A4 (fr)	2019-05-22	Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
ME03487B (fr)	2020-01-20	Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EP3302379A4 (fr)	2019-01-23	Compositions et méthodes pour le traitement du ptérygion
EP3324978A4 (fr)	2019-01-30	Compositions d'oligonucléotides et méthodes associées
EP3328376A4 (fr)	2019-03-13	Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3347469A4 (fr)	2019-02-27	Méthodes et compositions pour le traitement du glaucome
MA41120A (fr)	2017-10-10	Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3390642A4 (fr)	2019-06-26	Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA41794A (fr)	2018-01-23	Agents thérapeutiques modifiés et compositions associées
EP3380095A4 (fr)	2019-10-23	Compositions et méthodes de traitement d'un avc ischémique
MA46750A (fr)	2019-09-18	Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
EP3512524A4 (fr)	2020-03-04	Méthodes et compositions de traitement d'infections virales
EP3405191A4 (fr)	2019-09-04	Méthodes et compositions pour le traitement de l'hyperhidrose
MA45226A (fr)	2019-04-17	Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3317290A4 (fr)	2019-04-10	Compositions et méthodes de traitement d'une infection virale
EP3368048A4 (fr)	2019-06-05	Méthodes et compositions pour le traitement de l'amyloïdose
MA52644A (fr)	2021-03-24	Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3522865A4 (fr)	2020-06-17	Méthodes et compositions pour le traitement de vergetures
MA43106A (fr)	2021-05-05	Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3365014A4 (fr)	2019-06-12	Méthodes et compositions pour le traitement de la mastocytose systémique
EP3493823C0 (fr)	2024-12-25	Composé à base de postbiotique pour le traitement de l'inflammation oculaire